IEHP UM Subcommittee Approved Authorizations Guidelines

Bone Marrow Transplant in the Treatment of Multiple Sclerosis

Policy:
On January 26, 2006, the UM Subcommittee determined that Bone Marrow Transplant in the Treatment of Multiple Sclerosis is investigational and not of proven value. The UM Subcommittee’s recommendation is to not cover this procedure at this time. Upon review in 2016, the guidelines remain unchanged.

Carrier Statements:
Bone Marrow Transplant for the treatment of Multiple Sclerosis is not currently reimbursed by Aetna, Cigna, Medical or Medicare.

Effective Date: January 26, 2008 Reviewed Annually: December 17, 2020

Revised:
May 11, 2016

Bibliography:


Disclaimer

IEHP Clinical Authorization Guidelines (CAG) are developed to assist in administering plan benefits, they do not constitute a description of plan benefits. The Clinical Authorization Guidelines (CAG) express IEHP's determination of whether certain services or supplies are medically necessary, experimental and investigational, or cosmetic. IEHP has reached these conclusions based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). IEHP makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in the Clinical Authorization Guidelines (CAG). IEHP expressly and solely reserves the right to revise the Clinical Authorization Guidelines (CAG), as clinical information changes.